Braf protein mutation and its significancy within patients with melanoma
نویسندگان
چکیده
Introduction and purpose: 
 This review aims to analyze BRAF mutation significancy its influence on progression therapy methods within patients with melanoma. Material method: was mainly based articles collected in Pubmed years 2004-2018. The research done by looking through keywords as follows “braf kinase”, mutation”, “melanoma” “wemurafenib”. Results: selected studies have demonstrated that it is justified identify patient due it’s treatment’s method choosing. Conclusions: Citied researches proven growth progressions of many malignant tumors. Further tests are likely not only prolong life expectancy melanoma, but also being a source crucial knowledge about tumors development.
منابع مشابه
BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma.
BACKGROUND B-Raf is a serine/threonine protein kinase activating the MAP kinase/ERK-signaling pathway. It has been shown that 50% of melanomas harbor activating BRAF mutations, with over 90% being the V600E mutation. OBJECTIVE The goal of this research was to determine the prevalence of the BRAF V600E mutation in patients from Central Mexico diagnosed with primary melanoma. METHODS Skin bio...
متن کاملthe past hospitalization and its association with suicide attempts and ideation in patients with mdd and comparison with bmd (depressed type) group
چکیده ندارد.
Amelanotic Melanoma Presenting with Plasmacytoid Morphology and BRAF V600 Mutation
Plasmacytoid melanoma is an unusual variant of malignant melanoma. The plasmacytoid morphology can be found in a variety of other malignancies including carcinomas, plasma cell neoplasms, lymphoproliferative disorders, and sarcomas. The authors report a rare case of plasmacytoid amelanotic malignant melanoma in a 78-year-old man presenting with an enlarging palpable, erythematous mass on his le...
متن کاملImproved survival with vemurafenib in melanoma with BRAF V600E mutation.
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. METHODS We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation. Pati...
متن کاملBRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
PURPOSE The prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma progression remains inconclusive. We investigated the prevalence and distribution of mutations in these genes in different melanoma tissues. PATIENTS AND METHODS In all, 291 tumor tissues from 132 patients with melanoma were screened. Paired samples of primary melanomas (n = 102) and synchronous or asynchronous meta...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Education, Health and Sport
سال: 2022
ISSN: ['2391-8306']
DOI: https://doi.org/10.12775/jehs.2022.12.08.076